

12th February, 2025

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

BSE Scrip Code: - 524500

NSE SYMBOL: - KILITCH

Sub: Press Release

Dear Sir,

Please find enclosed herewith our Press Release relating to Q325 financial results of the Company, which we shall be releasing after sending this letter to you.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876





Kilitch Drugs Limited Q3FY25 PAT registers 222% YoY remarkable growth and Revenue from operations rises up by 77% on consolidated basis

February 12, 2025, Mumbai - Kilitch Drugs Limited, BSE and NSE listed, a leading pharmaceutical company specializing in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent, announced its unaudited financial results for the quarter and nine months ended 31st December 2024.

The company's reported a 222% per cent year-on-year(Y-o-Y) remarkable rise in consolidated profit after tax (PAT) for the Q3 FY25 to Rs. 5.61 crore from Rs. 1.74 crore for the corresponding period previous year.

The company recorded its quarterly consolidated revenue from operations at Rs. 56.17 crore in Q3FY25, experiencing 77 per cent of Y-o-Y excellence growth from Rs. 31.79 crore in Q3 FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.

Consecutively, the company's standalone PAT rose by 25% per cent, and revenue grew by 56 per cent to Rs 6.88 crore and Rs 46.51 crore recorded in Q3 FY25, respectively.

For the nine months ending December 2024 (9MFY25), Kilitch reported an over 42 percent YoY rise in net profit to ₹19.78 crore, compared to ₹13.93 crore in 9MFY24. Revenue from operation for the period increased by 35 percent to ₹125.28 crore from ₹92.46 crore in the previous year.

Commenting on the Q3FY25 performance, Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs said, "We witnessed significant growth in our performance this quarter; revenue from operations grew by 35% on standalone basis. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders."

About Kilitch Drugs India Ltd:

Founded in 1978, Kilitch Drugs India Ltd is a leading pharmaceutical manufacturing company with existing manufacturing units in Mumbai, India, Ethiopia (Africa) and setting up a new green field project in Pen, Maharashtra India, which aims to develop and manufacture various pharmaceuticals including Injectables, Ophthalmic, OSD and Nutraceuticals, meeting regulatory requirements along with USFDA to approach across the globe. The company is a global innovator and has been consistently recognized for its excellence in quality, innovative processes, research and development, and sustainable product portfolio. Kilitch Drugs India Ltd has successfully established a foothold across several key African countries. Its manufacturing plant in Mumbai is equipped with specialized sections for dry powder formulations, small-volume liquid ampoules, and vials. The company's facilities are certified by multiple global authorities, including WHO GMP, ISO 9001, ISO 13485, PPB Kenya, NAFDAC Nigeria, FDA Ghana, MOH Sudan, Phillipines Pix Approvals, EFDA Ethiopia and many other countries. The company's product portfolio spans a wide range of therapeutic areas, including gastroenterology, anti-inflammatory, anti-malarial, ophthalmic, uterine stimulants, veterinary medicines, and many more.

For media queries, please contact:

Meeral Salia	Shivani Shah
M: +91 77383634559	M: +91 9334241876
E: meeral.s@sgal.net	E: shivani.s@sgal.net